Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term open-label study of delayed-release cysteamine bitartrate (RP103) versus Cystagon in cystinosis
NL-OMON43669Phase 3Active, not recruiting
- Sponsor
- Raptor Pharmaceuticals
- Start
- Jul 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of cysteamine in cystinosis (2 arms), sponsored by Raptor Pharmaceuticals. Primary endpoints: Superiority of RP103 versus Cystagon in controlling white blood cell cystine levels over 24 hours and Long-term safety and tolerability of RP103. Started Jul 2014; status: active, not recruiting.
02
Drugs
cysteamine
03
Conditions
cystinosis
Beyond the preview
Go deeper on NL-OMON43669.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON43669.